A double blind study to compare the acute and subchronic effects of ebastine 10, 20 and 30 mg o.d., triprolidine 10 mg o.d. and placebo on car driving performance.

Ebastine is a recently developed potent and selective H1- receptor antagonist for treatment of seasonal and perennial allergic rhinitis and idiopathic urticaria. In the present study 15 male subjects participated in testing the effects of ebastine 30, 20 and 10 mg o.d., triprolidine 10 mg o.d. and placebo on a standard driving test and on car following performance. The conclusion of this experiment is that ebastine up to 30 mg o.d. does not seem to impair safe driving behaviour.